News
Media or Investor Inquiries:
March, 2021
No Comments
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
Combined company renamed Nuvation Bio Inc., will be listed on the New York Stock Exchange under ticker symbol “NUVB” Strong cash position of approximately $830
February, 2021
No Comments
Nuvation Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK – January 8, 2021 – Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel
January, 2021
No Comments
Nuvation Bio Expands Executive Team with Appointment of Healthcare Investment Banking Leader Jennifer Fox as Chief Financial Officer
NEW YORK – October 26, 2020 – Nuvation Bio, Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of
October, 2020
No Comments
Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development
Leading institutional investors commit $500 million through concurrent equity investments Upon completion of the business combination, over $850 million of expected cash resources will be
October, 2020
No Comments
